1.42%)
-14.97%)
Back
2 MIN READ
MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release fourth quarter financial results for the three month period ended March 31, 2022 before markets open on Monday, May 16, 2022.
MediPharm’s executive management team will also host a conference call and audio webcast on Monday, May 16, 2022, at 8:30 a.m. eastern time to discuss the Company’s financial results and outlook.
Audio Conference Call Dial in Details:
Toll-free number: +1 (888) 330-2379 / International number: +1 (240) 789-2714 / Conference ID: 4921762
Participants are asked to dial in approximately 15 minutes before the start of the call.
Participants are asked to dial in approximately 15 minutes before the start of the call.
Audio Webcast:
An audio webcast will be available in the Events section of the MediPharm website https://www.medipharmlabs.com/
For those who are unable to participate on the live conference call or webcast, a replay will be available approximately one hour after completion of the call.
For those who are unable to participate on the live conference call or webcast, a replay will be available approximately one hour after completion of the call.
About MediPharm Labs Corp.
Founded in 2015, MediPharm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, API and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.
In 2021, MediPharm received a Drug Establishment Licence from Health Canada, becoming the only company in North America to hold a domestic Good Manufacturing Practices licence for the extraction of natural cannabinoids. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
For further information, please contact:
Investor Relations
Telephone: +1 416-913-7425
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com
Share
All good -- no spamming here.
Get the Latest Cannabis News & Stock Picks.
Comments